The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

A randomised controlled trial of micronised purified flavonoid fraction vs placebo in patients with chronic venous disease

På svenska

Author

  • Gudmundur Danielsson
  • C Jungbeck
  • Klas Peterson
  • Lars Norgren

Summary, in English

Objective: to evaluate the efficacy of a micromised purified flavonoid fraction (MPFF) in the treatment of chronic venous disease (CVD). Design: prospective doable blind, randomised, control shady. Patients and methods: one hundred and one patients with symptomatic CVD were randomly allocated to treatment for 60 days with either MPFF (51 patients) or placebo (50 patients) 500 mg twice daily. There were 28 men and 73 women, aged 22-65 years (mean age 48 years). No difference regarding age, gender, clinical class or duration of symptoms was recorded between the treatment and placebo groups. A global score for evaluation of symptoms was used. Patients were investigated with plethysmography (foot-volumetry) and duplex-ultrasonography before and after the treatment period. For statistical comparison Cochran-Mantel-Haenszel test, two-sided Student t-test and covariance analysis were used and p<0.05 was regarded significant. Results: improvement of the global score of symptoms was reported by 21 patients in the MPFF group and by 16 in the placebo group (N.S.). For the whole groups, no significant differences were recorded before and after treatment regarding foot-volumetric or ultrasonography parameters. On the other hand, in patients with edema (20 in the MPFF group, 23 in tire placebo group) ultrasonographic reflux time was significantly reduced for those in the treatment group (p=0.03). This finding did not correlate to clinical symptoms. Conclusion: in this study, MPFF dirt trot change the symptoms of CVD, except might cramps. A secondary finding was reduced reflux times in patients with oedema, although no ultrasonographic or foot-volumetric parameters changed significantly for the whole group. The role of MPFF in treatment of patients with CVD needs to be further analysed in a large population.

Publishing year

2002

Language

English

Pages

73-76

Publication/Series

European Journal of Vascular and Endovascular Surgery

Volume

23

Issue

1

Document type

Journal article

Publisher

Elsevier

Topic

  • Surgery

Keywords

  • flavonoid function
  • micronised purified
  • chronic venous disease
  • pharmacological treatment

Status

Published

ISBN/ISSN/Other

  • ISSN: 1532-2165